Paradigm Biocapital Advisors LP Bicycle Therapeutics PLC Transaction History

Paradigm Biocapital Advisors LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$16.75 - $26.1 $7.71 Million - $12 Million	-460,242 Reduced 12.42%	3,246,759 $80.8 Million
Q4 2023 Feb 14, 2024	BUY	$13.29 - $22.2 $859,783 - $1.44 Million	64,694 Added 1.78%	3,707,001 $67 Million
Q3 2023 Nov 14, 2023	BUY	$19.9 - $26.25 $33 Million - $43.5 Million	1,656,877 Added 83.45%	3,642,307 $73.2 Million
Q2 2023 Aug 14, 2023	BUY	$18.95 - $28.67 $3.2 Million - $4.84 Million	168,649 Added 9.28%	1,985,430 $50.7 Million
Q1 2023 May 15, 2023	BUY	$20.02 - $31.37 $11.7 Million - $18.3 Million	583,501 Added 47.31%	1,816,781 $38.6 Million
Q4 2022 Feb 14, 2023	BUY	$20.37 - $32.9 $1.52 Million - $2.45 Million	74,594 Added 6.44%	1,233,280 $36.5 Million
Q3 2022 Nov 14, 2022	BUY	$17.49 - $28.44 $1.93 Million - $3.13 Million	110,170 Added 10.51%	1,158,686 $27 Million
Q2 2022 Aug 15, 2022	BUY	$12.95 - $46.99 $13.6 Million - $49.3 Million	1,048,516 New	1,048,516 $17.6 Million

111

40.8M

39.6K

24.6K

Ticker BCYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,676,100
Market Cap $419M
Description
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The co...

Get notified when there are updates to the investment portfolio of Paradigm Biocapital Advisors LP, based on Form 13F filings with the SEC.

Stay updated on Paradigm Biocapital Advisors LP with notifications on news.